Cargando…

Triple negativity and young age as prognostic factors in lymph node-negative invasive ductal carcinoma of 1 cm or less

BACKGROUND: Whether a systemic adjuvant treatment is needed is an area of controversy in patients with node-negative early breast cancer with tumor size of ≤1 cm, including T1mic. METHODS: We performed a retrospective analysis of clinical and pathology data of all consecutive patients with node-nega...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kwon, Ji Hyun, Kim, Yu Jung, Lee, Keun-Wook, Oh, Do-Youn, Park, So Yeon, Kim, Jee Hyun, Chie, Eui Kyu, Kim, Sung-Won, Im, Seock-Ah, Kim, In-Ah, Kim, Tae-You, Park, In Ae, Noh, Dong-Young, Bang, Yung-Jue, Ha, Sung Whan
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2010
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2966467/ https://www.ncbi.nlm.nih.gov/pubmed/20946688 http://dx.doi.org/10.1186/1471-2407-10-557

Ejemplares similares

The clinicopathologic characteristics and prognostic significance of triple-negativity in node-negative breast cancer
por: Rhee, Jiyoung, et al.
Publicado: (2008)

Prognostic impact of clinicopathologic parameters in stage II/III breast cancer treated with neoadjuvant docetaxel and doxorubicin chemotherapy: paradoxical features of the triple negative breast cancer
por: Keam, Bhumsuk, et al.
Publicado: (2007)

Ki-67 can be used for further classification of triple negative breast cancer into two subtypes with different response and prognosis
por: Keam, Bhumsuk, et al.
Publicado: (2011)

Prognostic Value of p53 and bcl-2 Expression in Patients Treated with Breast Conservative Therapy
por: Kim, Kyubo, et al.
Publicado: (2010)

Palbociclib Plus Fulvestrant in Korean Patients from PALOMA-3 With Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer
por: Kim, Jee Hyun, et al.
Publicado: (2021)

A New Isolated Mediastinal Lymph Node or Small Pulmonary Nodule Arising during Breast Cancer Surveillance Following Curative Surgery: Clinical Factors That Differentiate Malignant from Benign Lesions
por: Kim, Tae-Yong, et al.
Publicado: (2014)

Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy
por: Lee, Kyung-Hun, et al.
Publicado: (2007)

Adjuvant concurrent chemoradiation therapy (CCRT) alone versus CCRT followed by adjuvant chemotherapy: Which is better in patients with radically resected extrahepatic biliary tract cancer?: a non-randomized, single center study
por: Lim, Kyu-Hyoung, et al.
Publicado: (2009)

Individualized Tumor Response Testing for Prediction of Response to Paclitaxel and Cisplatin Chemotherapy in Patients with Advanced Gastric Cancer
por: Kim, Jee Hyun, et al.
Publicado: (2010)

Concurrent Chemoradiotherapy Versus Chemotherapy Alone for Unresectable Locally Advanced Pancreatic Cancer: A Retrospective Cohort Study
por: Choi, Younak, et al.
Publicado: (2016)

Weekly Paclitaxel and Trastuzumab as a First-Line Therapy in Patients with HER2-Overexpressing Metastatic Breast Cancer: Magnitude of HER2/neu Amplification as a Predictive Factor for Efficacy
por: Han, Hye-Suk, et al.
Publicado: (2009)

Phase II Trial of Postoperative Adjuvant Gemcitabine and Cisplatin Chemotherapy Followed by Chemoradiotherapy with Gemcitabine in Patients with Resected Pancreatic Cancer
por: Lee, Kyung-Hun, et al.
Publicado: (2021)

Diagnostic performance of contrast enhanced CT and (18)F-FDG PET/CT in suspicious recurrence of biliary tract cancer after curative resection
por: Lee, Yun-Gyoo, et al.
Publicado: (2011)

Implications of Tamoxifen Resistance in Palbociclib Efficacy for Patients with Hormone Receptor–Positive, HER2-Negative Metastatic Breast Cancer: Subgroup Analyses of KCSG-BR15-10 (YoungPEARL)
por: Lee, Jiyun, et al.
Publicado: (2021)

Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells
por: Min, Ahrum, et al.
Publicado: (2015)

Predictive Significance of p53, Ki-67, and Bcl-2 Expression for Pathologic Complete Response after Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer
por: Kim, Taeryung, et al.
Publicado: (2015)

Exploratory analysis of biomarkers associated with clinical outcomes from the study of palbociclib plus endocrine therapy in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer
por: Lee, Soohyeon, et al.
Publicado: (2022)

Radiosensitization with combined use of olaparib and PI-103 in triple-negative breast cancer
por: Jang, Na Young, et al.
Publicado: (2015)

A Prognostic Model for Patients with Triple-Negative Breast Cancer: Importance of the Modified Nottingham Prognostic Index and Age
por: Kwon, Jeanny, et al.
Publicado: (2017)

Is a 22 cm Ureteric Stent Appropriate for Korean Patients Smaller than 175 cm in Height?
por: Lee, Byung Ki, et al.
Publicado: (2010)

Treatment outcomes and prognostic factors of gallbladder cancer patients after postoperative radiation therapy
por: Kim, Suzy, et al.
Publicado: (2011)

Prognostic Value of Splenic Artery Invasion in Patients Undergoing Adjuvant Chemoradiotherapy after Distal Pancreatectomy for Pancreatic Adenocarcinoma
por: Kim, Byoung Hyuck, et al.
Publicado: (2015)

Evaluation of the Survival Benefit of Different Chemotherapy Regimens in Patients with T1-2N0 Triple-Negative Breast Cancer
por: Kim, Hyun-Ah, et al.
Publicado: (2015)

Accelerated whole breast irradiation in early breast cancer patients with adverse prognostic features
por: Lee, Sea-Won, et al.
Publicado: (2016)

Postoperative chemoradiotherapy in high risk locally advanced gastric cancer
por: Song, Sanghyuk, et al.
Publicado: (2012)

Prognostic Significance of Inner Quadrant Involvement in Breast Cancer Treated with Neoadjuvant Chemotherapy
por: Chang, Ji Hyun, et al.
Publicado: (2016)

Quality of life outcomes including neuropathy-associated scale from a phase II, multicenter, randomized trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine as first-line chemotherapy for HER2-negative metastatic breast cancer: Korean Cancer Study Group Trial (KCSG BR13-11)
por: Kim, Ji-Yeon, et al.
Publicado: (2019)

Breast cancer stem cells in HER2-negative breast cancer cells contribute to HER2-mediated radioresistance and molecular subtype conversion: clinical implications for serum HER2 in recurrent HER2-negative breast cancer
por: Kim, Yun Gyoung, et al.
Publicado: (2017)

Postmastectomy Radiation Therapy for Node-Negative Breast Cancer of 5 cm or Larger Tumors: A Multicenter Retrospective Analysis (KROG 20-03)
por: Kim, Kyubo, et al.
Publicado: (2022)

Body Mass Index Is Not Associated with Treatment Outcomes of Breast Cancer Patients Receiving Neoadjuvant Chemotherapy: Korean Data
por: Lee, Kyung-Hun, et al.
Publicado: (2012)

MicroRNA‑606 inhibits the growth and metastasis of triple‑negative breast cancer by targeting Stanniocalcin 1
por: Choi, Sujin, et al.
Publicado: (2023)

Adjuvant Chemotherapy in Microsatellite Instability–High Gastric Cancer
por: Kim, Jin Won, et al.
Publicado: (2020)

The influence of the treatment response on the impact of resection margin status after preoperative chemoradiotherapy in locally advanced rectal cancer
por: Lee, Joo Ho, et al.
Publicado: (2013)

TGF-β Suppresses COX-2 Expression by Tristetraprolin-Mediated RNA Destabilization in A549 Human Lung Cancer Cells
por: Kang, Soyeong, et al.
Publicado: (2015)

Microinvasive Carcinoma versus Ductal Carcinoma In Situ: A Comparison of Clinicopathological Features and Clinical Outcomes
por: Kim, Milim, et al.
Publicado: (2018)

Natural Course of Asymptomatic Upper Gastrointestinal Subepithelial Lesion of 2 cm or Less in Size
por: Kim, Donghyun, et al.
Publicado: (2022)

TDP1 and TOP1 Modulation in Olaparib-Resistant Cancer Determines the Efficacy of Subsequent Chemotherapy
por: Kim, Jin Won, et al.
Publicado: (2020)

Anti-tumor activity of BET inhibitors in androgen-receptor-expressing triple-negative breast cancer
por: Park, In Hae, et al.
Publicado: (2019)

Antitumor effect of a WEE1 inhibitor and potentiation of olaparib sensitivity by DNA damage response modulation in triple-negative breast cancer
por: Ha, Dong-Hyeon, et al.
Publicado: (2020)

Effect of Time Interval between Breast-Conserving Surgery and Radiation Therapy on Outcomes of Node-Positive Breast Cancer Patients Treated with Adjuvant Doxorubicin/Cyclophosphamide Followed by Taxane
por: Koh, Hyeon Kang, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_ei3f8l1pmoa3gjip59hs7356oc